PMID- 36418528
OWN - NLM
STAT- MEDLINE
DCOM- 20230203
LR  - 20240202
IS  - 1548-3576 (Electronic)
IS  - 1548-3568 (Print)
IS  - 1548-3568 (Linking)
VI  - 20
IP  - 1
DP  - 2023 Feb
TI  - Diabetes in HIV: the Link to Weight Gain.
PG  - 9-18
LID - 10.1007/s11904-022-00642-w [doi]
AB  - PURPOSE OF REVIEW: The burden of metabolic diseases, including type 2 diabetes 
      mellitus (T2DM), is rising among persons with HIV (PWH) on antiretroviral therapy 
      (ART). This increase coincides with an aging population and a greater proportion 
      who are overweight/obese. This review summarizes the changing epidemic of T2DM on 
      contemporary ART, the role of weight gain, and therapeutic options. RECENT 
      FINDINGS: Recent studies confirm that PWH face an epidemic of obesity and T2DM, 
      similar to the general population. Contemporary ART is associated with greater 
      weight gain and may contribute to the risk of T2DM. Recent advances in medical 
      weight loss therapy offer a way forward in the prevention and treatment of 
      weight-associated T2DM. Weight gain is one of the biggest contributors to T2DM in 
      PWH. Future studies on the role of adipose tissue distribution, adipose tissue 
      function and clinical use of effective weight loss medications may change the 
      paradigm of care for PWH.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Bailin, Samuel S
AU  - Bailin SS
AUID- ORCID: 0000-0003-4990-1013
AD  - Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, 
      37232, USA. samuel.bailin@vumc.org.
FAU - Koethe, John R
AU  - Koethe JR
AD  - Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, 
      37232, USA.
AD  - Department of Veterans Affairs, Tennessee Valley Health System, Nashville, TN, 
      37212, USA.
LA  - eng
GR  - K12 HL143956/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20221123
PL  - United States
TA  - Curr HIV/AIDS Rep
JT  - Current HIV/AIDS reports
JID - 101235661
SB  - IM
MH  - Humans
MH  - Aged
MH  - *Diabetes Mellitus, Type 2/complications/epidemiology
MH  - *HIV Infections/complications/drug therapy/epidemiology
MH  - Weight Gain
MH  - Obesity/complications/epidemiology
MH  - Weight Loss
PMC - PMC10184162
MID - NIHMS1892486
OTO - NOTNLM
OT  - Human immunodeficiency virus
OT  - Obesity
OT  - Type 2 diabetes
OT  - Weight gain
COIS- Conflict of Interest S.B. has no competing interests to declare. J.K. has served 
      as a consultant to Gilead Sciences, Merck & Co., ViiV Healthcare, 
      Theratechnologies and Janssen Pharmaceuticals. He has also received research 
      support from Gilead Sciences and Merck & Co.
EDAT- 2022/11/24 06:00
MHDA- 2023/02/04 06:00
PMCR- 2024/02/01
CRDT- 2022/11/23 23:39
PHST- 2022/10/05 00:00 [accepted]
PHST- 2022/11/24 06:00 [pubmed]
PHST- 2023/02/04 06:00 [medline]
PHST- 2022/11/23 23:39 [entrez]
PHST- 2024/02/01 00:00 [pmc-release]
AID - 10.1007/s11904-022-00642-w [pii]
AID - 10.1007/s11904-022-00642-w [doi]
PST - ppublish
SO  - Curr HIV/AIDS Rep. 2023 Feb;20(1):9-18. doi: 10.1007/s11904-022-00642-w. Epub 
      2022 Nov 23.